<DOC>
	<DOCNO>NCT02546960</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability different dose JNJ-63871860 ( ExPEC4V ) participant great equal ( &gt; = ) 18 year age evaluate dose-dependent immunogenicity ExPEC measure enzyme-linked immunosorbent assay ( ELISA ) .</brief_summary>
	<brief_title>A Study Healthy Adults Evaluate Safety Immunogenicity Different Doses JNJ-63871860</brief_title>
	<detailed_description>This Phase 2 , double-blind ( neither researcher participant know treatment participant receiving ) , randomize ( study medication assign participant chance ) , placebo-controlled ( inactive substance ; pretend treatment [ drug ] compare clinical trial drug test drug real effect ) , parallel group , multicenter ( one hospital work medical research study ) study , single-blind , long-term follow-up Year 4 . The study split 2 phase , double-blind phase screening ( Day -12 Day 1 ) , Vaccination ( Day 1 ) Safety Immunogenicity Follow-up ( Day 1 Day 360 ) , single-blind long-term follow-up phase thereafter Year 4 placebo participant ExPEC4V participant dose group select base primary ( Day 30 ) analysis . Participants stratify 2 age group ( &gt; =18 le [ &lt; ] 50 year &gt; =50 year ) dose group stratum randomize single vaccination 1 5 dos ExPEC4V placebo . The duration double-blind phase ( randomization/vaccination ) approximately 360 day placebo participant participant dose group select base primary analysis , approximately 180 day participant group . The duration single-blind long-term follow-up phase approximately 3 year double-blind phase placebo participant participant select dose group . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant must stable health . Participants may underlie illness hypertension , diabetes , ischemic heart disease , hyperlipoproteinemia , hypothyroidism , long symptoms/signs medically control . If medication condition , medication dose must stable least 12 week precede vaccination expect remain stable duration study Participant must meet protocol define laboratory criterion within 12 day Day 1 Participant must able attend schedule visit comply study procedure Participant must body mass index ( BMI ) less equal ( &lt; = ) 35 kilogram per square meter ( kg/m^2 ) A woman childbearing potential must negative urine pregnancy test Day 1 vaccination Participant woman pregnant , breastfeeding , positive urine pregnancy test Day 1 vaccination , plan become pregnant 3 month study vaccine administration within 3 month study vaccine administration , subject man plan father child enrol study within 3 month study vaccine administration Participant acute illness , acute infection , fever ( body temperature great equal [ &gt; = ] 38 degree Celsius ) Participant serious chronic disorder , include severe chronic obstructive pulmonary disease clinically significant congestive heart failure , requirement supplemental oxygen , end stage renal disease without dialysis , clinically unstable cardiac disease , condition , opinion investigator , participation would best interest subject ( example compromise wellbeing ) could prevent , limit , confound protocolspecified assessment Participant history neoplastic disease ( exclude nonmelanoma skin cancer successfully treat ) within past 5 year history hematological malignancy Participant know suspect congenital acquired immunodeficiency ( include leukemia , HIV seropositivity ) , receive immunosuppressive therapy ( anticancer chemotherapy , radiation therapy cytotoxic drug ) , within precede 6 month ; longterm systemic corticosteroid therapy [ prednisone equivalent 2 consecutive week within past 3 month ] ) , chronic active hepatitis B hepatitis C infection , document hepatitis B surface antigen hepatitis C antibody , respectively</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-63871860</keyword>
	<keyword>ExPEC4V</keyword>
</DOC>